Laboratory of Ophthalmology, KU Leuven, Leuven, BelgiumDepartment of Ophthalmology, University Hospitals Leuven, Leuven, BelgiumDepartment of Ophthalmology, Centro Hospitalar de Lisboa Central, Lisbon, PortugalDepartment of Ophthalmology, University of Iceland, Reykjavik, Iceland.
Acta Ophthalmol. 2013 Dec;91(8):733-7. doi: 10.1111/j.1755-3768.2012.02545.x. Epub 2012 Sep 23.
To test whether adding topical phenylephrine 5% to tropicamide 0.5% eye drops in the protocol for pupil dilation affects the retinal vessel oximeter measurements in patients with glaucoma. To test whether phenylephrine 5% has an influence as a vasoconstrictor on the retinal vessel width and can improve the proportion of high-quality retinal images in patients with glaucoma.
Retinal images of 66 patients with chronic open-angle glaucoma were obtained before and after the administration of phenylephrine 5% eye drops to patients already dilated with tropicamide 0.5% with the Oxymap Retinal Oximeter (Oxymap ehf, Reykjavik, Iceland). Specialized software, Oxymap Analyzer, analysed the images and measured the oxygen saturation and vessel diameter. Oxygen saturation was measured in first- and second-degree vessels. A Mann-Whitney U-test was used to compare both groups. Quality of the images was assessed, and a Fisher's exact test was used to compare the proportion of high- and poor-quality images.
There was no significant difference in arterial and venous oxygen saturation in patients with glaucoma whether dilated by tropicamide alone or a combination of tropicamide and phenylephrine (97 ± 6% versus 96 ± 5%, p = 0.88 for arterial saturation and 66 ± 6% versus 67 ± 6%, p = 0.78 for venous saturation, n = 27). There was no significant difference in vessel diameter between both conditions for the different vessels (p = 0.61 for arterial saturation and p = 0.51 for venous saturation, n = 27). The proportion of high-quality images was significantly higher after the combination regimen compared with tropicamide only (p = 0.0001).
The addition of topical phenylephrine 5% after tropicamide 0.5% improved the proportion of high-quality retinal oximetry images without influencing the retinal oxygen saturation values or the retinal vessel diameter in patients with glaucoma.
测试在瞳孔扩张方案中添加局部苯肾上腺素 5%是否会影响青光眼患者的视网膜血管血氧计测量值。测试苯肾上腺素 5%是否作为血管收缩剂影响视网膜血管宽度,并能改善青光眼患者的高质量视网膜图像比例。
使用 Oxymap 视网膜血氧计(Oxymap ehf,雷克雅未克,冰岛),对已经用托吡卡胺 0.5% 散瞳的 66 例慢性开角型青光眼患者,在给予苯肾上腺素 5%滴眼后,获取视网膜图像。专用软件 Oxymap Analyzer 分析图像并测量氧饱和度和血管直径。在一级和二级血管中测量氧饱和度。采用 Mann-Whitney U 检验比较两组。评估图像质量,并采用 Fisher 确切检验比较高质量和低质量图像的比例。
单独使用托吡卡胺或托吡卡胺联合苯肾上腺素散瞳的青光眼患者,动脉和静脉血氧饱和度均无显著差异(动脉饱和度分别为 97 ± 6%和 96 ± 5%,p = 0.88;静脉饱和度分别为 66 ± 6%和 67 ± 6%,p = 0.78,n = 27)。不同血管之间,两种情况下的血管直径均无显著差异(动脉饱和度 p = 0.61,静脉饱和度 p = 0.51,n = 27)。与单独使用托吡卡胺相比,联合方案后高质量图像的比例显著更高(p = 0.0001)。
在托吡卡胺 0.5%之后添加局部苯肾上腺素 5%可提高高质量视网膜血氧计图像的比例,而不影响青光眼患者的视网膜氧饱和度值或视网膜血管直径。